Glioblastoma

Pathophysiology

Glioblastoma is the most common malignant central nervous system tumor that occurs almost exclusively in the brain.1-3 Primary glioblastoma typically occurs in elderly patients and originates from healthy glial tissue, whereas secondary glioblastoma predominantly occurs in younger patients and arises from malignant changes in lower-grade gliomas.2,4 Genetic alterations in glioblastoma include loss of heterozygosity and alterations and deletions that impact cell survival, proliferation, and signaling pathways.1-3

Landscape

Treatment of glioblastoma remains challenging due in part to the difficulty of targeting the central nervous system and allowing therapeutics to cross the blood-brain barrier.2,3 Surgery is typically a treatment option for patients with glioblastoma, but resection rarely removes all tumor cells.1,3,4

Research is focused on investigating alkylating agents, targeted therapies (to inhibit angiogenesis, proteasomes, and receptor tyrosine kinases and their ligands and signaling pathways), immunotherapies, and immune checkpoint inhibitors.1-3,5

Read more Collapse

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

View Molecular Pathways

In Our Pipeline

Choose filters to find specific trials in the BMS pipeline.

Filter trials by:

STATUS

PHASE

trials
View Glioblastoma Trials Through Our Pipeline

To search for clinical trials with other recruiting statuses,
please visit bolderscience.com.

Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

References

  1. Davis ME. Clin J Oncol Nurs. 2016;20:S2-S8. PMID: 27668386
  2. Pearson JRD, Regad T. Signal Transduct Target Ther. 2017;2:17040. PMID: 29263927
  3. Shergalis A, et al. Pharmacol Rev. 2018;70:412-445. PMID: 29669750
  4. Joshi SK, et al. World J Neurol. 2015;5:88-101.
  5. Fulda S. Cell Death Dis. 2018;9:121. PMID: 29371590